B7-H3: an emerging solid tumor target with promise for antibody-drug conjugates

STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: B7-H3-Targeted Immunotherapy: a Competitor Analysis.

B7-H3 is a transmembrane protein that belongs to the B7 family, which also includes PD-L1. B7-H3 is overexpressed in a wide range of cancer types, including lung, prostate and esophageal, and its overexpression has been shown to correlate with poor prognosis in some cancers, making B7-H3 a promising therapeutic target. At the same time, B7-H3 is expressed at a low level in normal tissues. In malignant tissues, B7-H3 inhibits tumor antigen-specific immune responses, resulting in a protumorigenic effect. Additionally, B7-H3 promotes migration and invasion, angiogenesis, chemotherapy resistance, endothelial-to-mesenchymal transition, and affects tumor cell metabolism.

There are no B7-H3 directed medicines approved for the treatment of any cancer, but a number of effector-enhanced B7-H3-targeted immunotherapy candidates in preclinical and clinical development. More than 15 product candidates are in clinical development, with several already in clinical phase III. B7-H3 is an ideal target for antibody drug conjugates (ADC). Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models.

This product consists of a competitor description and analysis in a tabular format provided as a pdf document which is sent by e-mail within one day, usually within one hour. The pdf report includes a compilation of active projects in research and development of B7-H3-targeted product candidates.

The report “B7-H3-Targeted Immunotherapy: a Competitor Analysis” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/b7-h3-targeted-immunotherapy-a-competitor-analysis/